Risultati per: Tumore colon: trovate le cellule che formano le metastasi

Domani ad Ancona congresso scientifico alla Politecnica Marche

Report ‘I numeri del cancro’, -46% di decessi nelle donne per quello al polmone

Report ‘I numeri del cancro’, -46% di decessi nelle donne per il polmone

Iniziativa EuropaColon Italia e Pierre Fabre per tutto dicembre

In alcuni casi di recidiva si possono colpire mutazioni geniche

Pravettoni e Boldrini, ‘la malattia può essere anche un’opportunità di crescita’

Background
Colonic motility in constipation can be assessed non-invasively using MRI.

Objective
To compare MRI with high-resolution colonic manometry (HRCM) for predicting treatment response.

Design
Part 1: 44 healthy volunteers (HVs), 43 patients with irritable bowel syndrome with constipation (IBS-C) and 37 with functional constipation (FC) completed stool diaries and questionnaires and underwent oral macrogol (500–1000 mL) challenge. Whole gut transit time (WGTT), segmental colonic volumes (CV), MRI-derived Motility Index and chyme movement by ‘tagging’ were assessed using MRI and time to defecation after macrogol recorded. Left colonic HRCM was recorded before and after a 700 kcal meal. Patients then proceeded to Part 2: a randomised cross-over study of 10-days bisacodyl 10 mg daily versus hyoscine 20 mg three times per day, assessing daily pain and constipation.

Results
Part 1: Total CVs median (range) were significantly greater in IBS-C (776 (595–1033)) and FC (802 (633–951)) vs HV (645 (467–780)), p

Cnr, nuovo approccio potrebbe migliore sopravvivenza pazienti

Potrà essere usato per la diagnosi delle forme più aggressive

Ruolo chiave per una proteina, possibili ricadute terapeutiche

Esperto, ‘Una nuova speranza per migliorare la sopravvivenza e la qualità di vita dei pazienti’

ERBB2-pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. We compared molecular methods to the gold-standard for assessing ERBB2 status and determined the prognostic value of ERBB2 amplification, mutations, and expression using data from two phase III trials involving nearly 3,000 stage III CC patients.

Edita da Gilead, presentata a Firenze e disponibile online

Da Torino l’annuncio di un passo avanti nella lotta al cancro

Via a studio con Italia.Biopsia liquida per nuovo approccio cura